Search





Search





Markets
/
Stocks
/
nasdaq-qnrx
/

Quoin Pharmaceuticals Ltd

QNRX

Add to Watchlist

5.790USD

-0.060-1.03%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

303.64MMarket Cap

LossP/E TTM



Quoin Pharmaceuticals Ltd

5.790

-0.060-1.03%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Quoin Pharmaceuticals Ltd

Currency: USD Updated: 2026-05-15

Key Insights

Quoin Pharmaceuticals Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 182 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.75.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Quoin Pharmaceuticals Ltd's Score

Industry at a Glance

Industry Ranking

182 / 382

Overall Ranking

329 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Quoin Pharmaceuticals Ltd Highlights

StrengthsRisks

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -0.39, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 874.98K shares, increasing 29.68% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

29.750

Target Price

+412.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Quoin Pharmaceuticals Ltd is 6.96, ranking 153 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.96

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Quoin Pharmaceuticals Ltd's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Quoin Pharmaceuticals Ltd is 7.16, ranking 150 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.39, which is -28202.63% below the recent high of 109.97 and -1657753.18% above the recent low of -6487.18.

Score

Industry at a Glance

Previous score

7.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 182/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Quoin Pharmaceuticals Ltd is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 70.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

29.750

Target Price

+412.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Quoin Pharmaceuticals Ltd

QNRX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Quoin Pharmaceuticals Ltd is 2.94, ranking 367 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.59 and the support level at 5.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.94

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.051

Neutral

RSI(14)

42.150

Neutral

STOCH(KDJ)(9,3,3)

26.347

Sell

ATR(14)

0.460

High Vlolatility

CCI(14)

-105.460

Sell

Williams %R

60.407

Sell

TRIX(12,20)

-0.297

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.972

Sell

MA10

6.126

Sell

MA20

6.013

Sell

MA50

6.769

Sell

MA100

8.454

Sell

MA200

9.678

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Quoin Pharmaceuticals Ltd is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 43.66%, representing a quarter-over-quarter increase of 44.22%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ikarian Capital LLC

211.54K

Stonepine Capital Management, LLC

93.46K

+19.53%

Woodline Partners LP

79.58K

abrdn Inc.

75.00K

Millennium Management LLC

74.82K

Crestline Investors, Inc.

64.80K

Boothbay Fund Management, LLC

59.84K

Adar1 Capital Management LLC

58.23K

AIGH Capital Management, LLC.

36.00K

Resolute Capital Asset Partners LLC

30.00K

-40.00%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Quoin Pharmaceuticals Ltd is 1.09, ranking 336 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.